FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms

Accepted/In Press date: 23 June 2022

Published date: 19 July 2022

Additional Information: Funding Information: We thank members of the Antibody and Vaccine Group and BioInvent International for useful discussions and the pre-clinical unit staff for animal husbandry. Funding was from Blood Cancer UK (award numbers 12050 and 14043 ), CRUK (award numbers A18087 , A24721 , A25139 ), and BioInvent International . A.P.S was supported by an iCASE studentship from the BBSRC ( 1943869 ) in association with GSK. Funding Information: We thank members of the Antibody and Vaccine Group and BioInvent International for useful discussions and the pre-clinical unit staff for animal husbandry. Funding was from Blood Cancer UK (award numbers 12050 and 14043), CRUK (award numbers A18087, A24721, A25139), and BioInvent International. A.P.S was supported by an iCASE studentship from the BBSRC (1943869) in association with GSK. A.P.S. designed and performed experiments, analyzed and interpreted data, and wrote the manuscript. A.R. designed and performed experiments, supervised data collection, analyzed and interpreted data, and edited the manuscript. R.O. H.T.C. K.L.C. Y.B. S.J. and L.N.D. designed and performed experiments. C.P. J.K. T.I. I.M. and A.T. generated or provided key reagents or performed and analyzed research. D.R. and P.M. helped design the study, supervised data collection, and discussed and interpreted data. I.T. helped design the study, supervised data collection, and discussed and interpreted data. B.F. S.A.B. and M.S.C. designed the study, supervised data collection, discussed and interpreted data, and wrote the manuscript. M.S.C. acts as a consultant for a number of biotech companies, being retained as a consultant for BioInvent International, and has received research funding from BioInvent International, GSK, UCB, iTeos, and Roche. S.A.B. has acted as a consultant for a number of biotechs and receives institutional support for grants and patents from BioInvent. A.R. receives institutional support for grants and patents from BioInvent International. D.R. and P.M. are employees of GSK. I.T. and B.F. are employees of BioInvent International. This work is related to patent family EP3263602A1 concerning the combined use of FcγRIIB and CD20-specific antibodies as well as US 11001638 and WO2019020774-A2/A3, relating to OX40 and 4-1BB. Publisher Copyright: © 2022 The Author(s)

Keywords: B cells, CP: Immunology, Fc receptors, FcγRIIB, ITIM, Treg, cancer, depletion, immunotherapy, monoclonal antibody

Local EPrints ID: 469109

URI: http://eprints.soton.ac.uk/id/eprint/469109

DOI: doi:10.1016/j.celrep.2022.111099

ISSN: 2211-1247

PURE UUID: 78a7488a-0bfe-4ba8-9678-d1d9abdb82d3

ORCID for Ali Roghanian: orcid.org/0000-0003-1316-4218

ORCID for Robert James Oldham: orcid.org/0000-0002-8007-1145

ORCID for Claude Chan: orcid.org/0000-0003-0530-9480

ORCID for Yury Bogdanov: orcid.org/0000-0003-4667-5890

ORCID for Stephen Beers: orcid.org/0000-0002-3765-3342

ORCID for Mark Cragg: orcid.org/0000-0003-2077-089X

Date deposited: 06 Sep 2022 18:49

Last modified: 06 Jun 2024 01:58